We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC EXTENDS ANTITRUST REVIEW OF GENZYME-ILEX DEAL
FTC EXTENDS ANTITRUST REVIEW OF GENZYME-ILEX DEAL
April 30, 2004
The FTC has asked for more information about Genzyme’s plans to acquire Ilex Oncology, thus extending the time the agency has to review the planned transaction for potential antitrust complications, the two companies announced last week.